'FRONTEO and EA Pharma Collaborate in Drug Discovery, AI Analyzes Medical Papers' was published in the Nikkei Online Edition...

The Nikkei Online Edition (dated May 5th) featured an article entitled "FRONTEO and EA Pharma Collaborate in Drug Discovery: AI Analyses Medical Papers."

■Article URL
https://www.nikkei.com/article/DGXZQOUC0996J0Z00C25A5000000/

■About FRONTEO's co-creation project
In general AI-based drug discovery solutions, the results of dry research (data analysis) and wet research (biological testing using cells, animals, etc.) are often submitted without active exchange of opinions or sharing of sensitive information between the companies in charge of the latter. This is one of the reasons why a smooth transition to wet validation cannot be made.
In this important process of moving from dry to wet, the co-creation project aims to create deliverables that maximize the synergistic effects of incorporating the knowledge and technologies possessed by both FRONTEO and the client company's drug discovery researchers through close collaboration (co-creation) across boundaries.
It is expected that this initiative will also contribute significantly to improving the success rate of clients' drug development in similar projects currently under discussion with multiple pharmaceutical companies.

[Reference: Co-creation project with pharmaceutical companies]
・EA Pharma and FRONTEO launch co-creation project to explore drug discovery targets using AI, https://www.fronteo.com/pr/20250512
・FRONTEO and Eisai launch co-creation project for target discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250128
・FRONTEO and Maruishi Pharmaceutical launch a co-creation project for biomarker discovery using Drug Discovery AI Factory, https://www.fronteo.com/pr/20250109
・FRONTEO and UBE launch co-creation project on drug repositioning using Drug Discovery AI Factory, https://www.fronteo.com/pr/20241114